Trials / Completed
CompletedNCT04145856
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
Efficacy of the Combination Therapy With Alverine-simeticone and i3.1 Probiotic Formula in the Quality of Life of Patients With IBS-D or IBS-M in Hospital Juarez Mexico
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Hospital Juarez de Mexico · Other Government
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Not accepted
Summary
This randomized study evaluates the usefulness of the I31 probiotic formula, alone or in combination with alverine/simethicone, against placebo, in the treatment of diarrhea-predominant or mixed irritable bowel syndrome
Detailed description
Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disease in which recurrent abdominal pain is associated with defecation or a change in bowel habits. Disordered bowel habits are typically present (ie, constipation, diarrhea, or a mix of constipation and diarrhea), as are symptoms of abdominal bloating/distention. I31 is a probiotic formula composed of strains Pediococcus acidilactici CECT7483 and Lactobacillus plantarum CECT7484 and CECT7485, previously shown to improve quality of life in patients with IBS of Caucasian descent. Alverine/simethicone is a combination of two drugs: Alverine citrate relaxes muscle cramps that occur in the intestine in conditions such as irritable bowel syndrome and diverticulosis. Simethicone is an antifoam administered orally. Reduces gas formation and facilitates its elimination from the digestive tract
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | I31 probiotic | I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d) |
| COMBINATION_PRODUCT | I31 probiotic combined to Alverine/Simethicone | * I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d) * Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d) |
| OTHER | Placebo | Placebo treatment (maltodextrin), once daily (u.i.d) |
Timeline
- Start date
- 2018-09-03
- Primary completion
- 2019-05-02
- Completion
- 2019-08-27
- First posted
- 2019-10-31
- Last updated
- 2020-01-23
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT04145856. Inclusion in this directory is not an endorsement.